MLN4924: A novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Pevonedistat 100%
• Clinical Trial 20%
• Neoplasm 20%
• Anticarcinogen 20%
• Ubiquitin 20%
• Phase I Trials 20%
• Ubiquitin Protein Ligase E3 20%
• Cancer Model 20%
• Functional Status 20%
• Cullin 20%
• Enzyme Inhibitor 20%

Biochemistry, Genetics and Molecular Biology

• Enzyme 100%
• NEDD8 100%
• Anticancer 22%
• Small Molecule 11%
• Clinical Trial 11%
• Ubiquitin 11%
• Protein Catabolism 11%
• Enzyme Inhibitor 11%
• Ubiquitin-Conjugating Enzyme 11%
• Functional Status 11%
• Phase I Trials 11%
• Targeting Protein 11%
• Neddylation 11%
• Cullin 11%

Keyphrases

• Cullin-RING E3 Ligase 16%